For instance, enriched HSP90 expression in the therapy-resistant BCR-ABL1+ leukemia subgroup facilitates proper folding of BCR-ABL1 oncoprotein, providing a rationale to target leukemia cells via HSP90 inhibition-mediated BCR-ABL1 oncoprotein degradation (Bhatia et al., 2018). This evidence concerns the gene ABL1 and leukemia.